PMC:4939752 / 20155-20586 JSONTXT

{"project":"2_test","denotations":[{"id":"27413424-11133748-56394055","span":{"begin":427,"end":429},"obj":"11133748"},{"id":"27413424-11133748-56394055","span":{"begin":427,"end":429},"obj":"11133748"},{"id":"T82833","span":{"begin":427,"end":429},"obj":"11133748"},{"id":"T57848","span":{"begin":427,"end":429},"obj":"11133748"}],"text":"A number of CD20 mAbs are now used in clinical practice or are in different stages of development (Table 3). Most of them such as rituximab, 90Y-Ibritumomab, tositumomab, ofatumumab and Obinutuzumab (GA 101) have been FDA approved for use in NHLs and RA. All anti-CD20 mAbs are biochemically and functionally divided into two distinct subtypes such as rituximab-like type I and tositumomab-like type II as shown in Table 2 [75,76]."}